EGFR and lung adenocarcinoma: First, most existing evidence is derived from heterogeneous NSCLC cohorts without histologic stratification; the distinct molecular characteristics of lung adenocarcinoma, such as high EGFR mutation frequency, may uniquely influence bone microenvironmental dynamics and therapeutic responses, necessitating subtype-specific analyses.